Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 3, 2026, 1:16 PM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 649–672 of 4,980 matching trials from the live ClinicalTrials.gov search.
Filters: San Diego, California Clear all
Completed Not applicable Interventional Results available

HOPE in Action Prospective Multicenter, Clinical Trial of Deceased HIVD+ Kidney Transplants for HIV+ Recipients

NCT03500315
View directory record Official record
Conditions
Hiv
Interventions
HIV D+/R+
Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
207 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
29
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Los Angeles, California + 18 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Nov 3, 2026, 1:16 PM EST
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Consent for Use of Stored Patient Specimens for Future Testing

NCT00031408
View directory record Official record
Conditions
HIV Infections
Interventions
Not listed
Lead sponsor
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Network
Eligibility
Not listed
Enrollment
17,444 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2027
U.S. locations
62
States / cities
Los Angeles, California • San Diego, California • San Francisco, California + 32 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2025 · Synced Nov 3, 2026, 1:16 PM EST
Not listed Not applicable Interventional Accepts healthy volunteers

Affixing Polypropylene Mesh Using Barbed Suture (Quill™ SRS) During Robotic Assisted Laparoscopic Sacrocolpopexy

NCT01608568
View directory record Official record
Conditions
Prolapse
Interventions
Device is the type of suture used: Quill suture vs. Interrupted suture
Device
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older · Female only
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Jun 1, 2012 · Synced Nov 3, 2026, 1:16 PM EST
Completed No phase listed Observational

A Gilead Sequence Registry of Subjects Who Did Not Achieve Sustained Virologic Response

NCT01457768
View directory record Official record
Conditions
Hepatitis C, Chronic
Interventions
Not listed
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
570 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
158
States / cities
Birmingham, Alabama • Dothan, Alabama • Phoenix, Arizona + 89 more
Source: ClinicalTrials.gov public record
Updated May 4, 2018 · Synced Nov 3, 2026, 1:16 PM EST
Completed Phase 1Phase 2 Interventional Results available

A Study of ABT-263 in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia

NCT00481091
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia
Interventions
ABT-263
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2022
U.S. locations
6
States / cities
La Jolla, California • Boston, Massachusetts • Omaha, Nebraska + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 13, 2023 · Synced Nov 3, 2026, 1:16 PM EST
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Comparing Buccal and Vaginal Misoprostol in Management of Early Pregnancy Loss

NCT02141555
View directory record Official record
Conditions
Spontaneous Abortion in First Trimester
Interventions
Vaginal Misoprostol, Buccal Misoprostol
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
4 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
2
States / cities
La Jolla, California • San Diego, California
Source: ClinicalTrials.gov public record
Updated Aug 15, 2019 · Synced Nov 3, 2026, 1:16 PM EST
Completed Phase 2 Interventional Results available

Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome & Immune Activation Markers

NCT02706717
View directory record Official record
Conditions
HIV-1 Infection
Interventions
Visbiome Extra Strength, Placebo
Drug
Lead sponsor
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Network
Eligibility
18 Years and older
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
24
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jan 6, 2020 · Synced Nov 3, 2026, 1:16 PM EST
Not yet recruiting Phase 3 Interventional

Personalized vs Standard of Care Treatment for Helicobacter Pylori Eradication Among Veterans

NCT07104318
View directory record Official record
Conditions
Helicobacter Pylori
Interventions
Bismuth quadruple therapy with optimized proton pump inhibitor (PPI), Bismuth quadruple therapy with standard proton pump inhibitor (PPI), Clarithromycin triple therapy with optimized proton pump inhibitor (PPI), Clarithromycin triple therapy with standard PPI, Standard bismuth quadruple therapy
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2030
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Nov 3, 2026, 1:16 PM EST
Active, not recruiting Phase 2 Interventional Results available

Study of Optimized Management of Nivolumab Based on Response in Patients With Advanced RCC (OMNIVORE Study)

NCT03203473
View directory record Official record
Conditions
Renal Cancer
Interventions
Ipilimumab, Nivolumab
Drug
Lead sponsor
Toni Choueiri, MD
Other
Eligibility
18 Years and older
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
8
States / cities
La Jolla, California • Chicago, Illinois • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Nov 3, 2026, 1:16 PM EST
Terminated Phase 2 Interventional Results available

Efficacy and Safety Trial of ADU-S100 and Pembrolizumab in Head and Neck Cancer

NCT03937141
View directory record Official record
Conditions
Metastatic Head and Neck Cancer, Recurrent Head and Neck Cancer
Interventions
ADU-S100
Drug
Lead sponsor
Chinook Therapeutics, Inc. (formerly Aduro)
Industry
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
17
States / cities
Birmingham, Alabama • Tucson, Arizona • La Jolla, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jan 3, 2022 · Synced Nov 3, 2026, 1:16 PM EST
Completed Phase 3 Interventional Results available

Study Of Pregabalin (Lyrica) In Patients With Painful Diabetic Peripheral Neuropathy

NCT01057693
View directory record Official record
Conditions
Diabetic Neuropathy, Painful
Interventions
pregabalin (Lyrica), Placebo
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years and older
Enrollment
633 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
150
States / cities
Birmingham, Alabama • Northport, Alabama • Gilbert, Arizona + 120 more
Source: ClinicalTrials.gov public record
Updated Jan 20, 2021 · Synced Nov 3, 2026, 1:16 PM EST
Terminated Not applicable Interventional

A Safety & Efficacy Study With Deep Transcranial Magnetic Stimulation for the Treatment of Post-Traumatic Stress Disorder (PTSD)

NCT02479906
View directory record Official record
Conditions
Post-Traumatic Stress Disorder
Interventions
Deep TMS System, Sham Treatment
Device
Lead sponsor
Brainsway
Industry
Eligibility
22 Years to 68 Years
Enrollment
203 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
12
States / cities
Los Angeles, California • Palo Alto, California • San Diego, California + 8 more
Source: ClinicalTrials.gov public record
Updated May 14, 2020 · Synced Nov 3, 2026, 1:16 PM EST
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Progestin-Only Pill Use and Breastfeeding Study

NCT04965116
View directory record Official record
Conditions
Contraception, Breastfeeding
Interventions
Progestin Only Contraceptive Pills
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older · Female only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Apr 19, 2024 · Synced Nov 3, 2026, 1:16 PM EST
Terminated Phase 3 Interventional Results available

Resuscitation Outcomes Consortium (ROC) Prehospital Resuscitation Using an Impedance Valve

NCT00394706
View directory record Official record
Conditions
Heart Arrest
Interventions
Impedance Threshold Device (ITD), Sham ITD, Analyze early, Analyze later
Device · Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
11,738 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
7
States / cities
Birmingham, Alabama • San Diego, California • Portland, Oregon + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2018 · Synced Nov 3, 2026, 1:16 PM EST
Completed Phase 3 Interventional Results available

A Study of Xeloda (Capecitabine) Plus Oxaliplatin in Patients With Colon Cancer

NCT00069121
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Capecitabine, Oxaliplatin, Leucovorin (LV), 5-Fluorouracil (5-FU)
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
1,886 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2011
U.S. locations
48
States / cities
Mobile, Alabama • Alhambra, California • Bakersfield, California + 43 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2020 · Synced Nov 3, 2026, 1:16 PM EST
Completed Phase 1 Interventional Results available

A Double-Blind, Multiple Ascending Dose Study to Assess Safety, Tolerability and Pharmacokinetics of DX-2930 in Hereditary Angioedema Participants

NCT02093923
View directory record Official record
Conditions
Hereditary Angioedema (HAE)
Interventions
DX-2930, Placebo
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
12
States / cities
San Diego, California • Walnut Creek, California • Tampa, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated May 27, 2021 · Synced Nov 3, 2026, 1:16 PM EST
Completed Phase 3 Interventional Results available

A Study of the Safety and Efficacy of Two Doses of Naltrexone SR/Bupropion SR and Placebo in Overweight and Obese Subjects

NCT00532779
View directory record Official record
Conditions
Obesity, Overweight
Interventions
Naltrexone SR 16 mg/Bupropion SR 360 mg /day, Naltrexone SR 32 mg/Bupropion SR 360 mg /day, Placebo, Ancillary therapy
Drug · Behavioral
Lead sponsor
Orexigen Therapeutics, Inc
Industry
Eligibility
18 Years to 65 Years
Enrollment
1,742 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
34
States / cities
Birmingham, Alabama • Fairhope, Alabama • Chandler, Arizona + 28 more
Source: ClinicalTrials.gov public record
Updated Nov 21, 2014 · Synced Nov 3, 2026, 1:16 PM EST
Not listed Phase 2 Interventional Accepts healthy volunteers

A Study to Evaluate Safety and Efficacy of KM-819 in Healthy Adults and Participants with Parkinson's Disease

NCT05670782
View directory record Official record
Conditions
Parkinson Disease
Interventions
KM-819, Placebo
Drug
Lead sponsor
FAScinate Therapeutics Inc.
Industry
Eligibility
40 Years and older
Enrollment
314 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
3
States / cities
Glendale, California • San Diego, California • Royal Oak, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 5, 2025 · Synced Nov 3, 2026, 1:16 PM EST
Active, not recruiting Phase 2 Interventional

Study to Assess the Adverse Events of Oral ABBV-932 in Adult Participants With Depressive Episodes Associated With Bipolar I or II Disorder

NCT07220460
View directory record Official record
Conditions
Bipolar I or II Disorder
Interventions
ABBV-932
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 65 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
47
States / cities
Phoenix, Arizona • Anaheim, California • Colton, California + 41 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Nov 3, 2026, 1:16 PM EST
Completed Phase 2 Interventional

Support, Health, and Fibromyalgia

NCT00000423
View directory record Official record
Conditions
Fibromyalgia, Quality of Life
Interventions
Social support group, Social support and education group
Behavioral
Lead sponsor
San Diego State University
Other
Eligibility
21 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2001
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Dec 4, 2013 · Synced Nov 3, 2026, 1:16 PM EST
Active, not recruiting Phase 3 Interventional

A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 )

NCT04849728
View directory record Official record
Conditions
NASH - Nonalcoholic Steatohepatitis
Interventions
IVA337, Placebo
Drug
Lead sponsor
Inventiva Pharma
Industry
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
194
States / cities
Birmingham, Alabama • Dothan, Alabama • Madison, Alabama + 142 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2026 · Synced Nov 3, 2026, 1:16 PM EST
Completed No phase listed Observational Accepts healthy volunteers

Brain Function in Adolescent Eating Disorders and Healthy Peers

NCT03347565
View directory record Official record
Conditions
Eating Disorder
Interventions
Not listed
Lead sponsor
University of California, San Diego
Other
Eligibility
14 Years to 17 Years · Female only
Enrollment
155 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2026
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Nov 3, 2026, 1:16 PM EST
Completed Phase 2 Interventional Results available

Oxytocin Suppresses Substance Use Disorders Associated With Chronic Stress

NCT02742532
View directory record Official record
Conditions
Alcohol Use Disorder, Stress Disorders, Post-Traumatic, Anxiety Disorders, Substance Use Disorders
Interventions
Oxytocin, Placebo
Drug
Lead sponsor
Jennifer Mitchell
Other
Eligibility
18 Years to 65 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Oct 19, 2020 · Synced Nov 3, 2026, 1:16 PM EST
Not listed Phase 2 Interventional

TPIV100 and Sargramostim for the Treatment of HER2 Positive, Stage II-III Breast Cancer in Patients With Residual Disease After Chemotherapy and Surgery

NCT04197687
View directory record Official record
Conditions
Breast Adenocarcinoma, Stage II Breast Cancer AJCC v6 and v7, Stage IIA Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7, Stage III Breast Cancer AJCC v7, Stage IIIA Breast Cancer AJCC v7, Stage IIIB Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7
Interventions
Multi-epitope HER2 Peptide Vaccine TPIV100, Pertuzumab, Placebo Administration, Sargramostim, Trastuzumab, Trastuzumab Emtansine
Biological · Other
Lead sponsor
Academic and Community Cancer Research United
Other
Eligibility
18 Years and older · Female only
Enrollment
480 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
30
States / cities
Scottsdale, Arizona • Tucson, Arizona • Yuma, Arizona + 26 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2023 · Synced Nov 3, 2026, 1:16 PM EST